Combined aromatase, CDK4/6 and PI3K blockade using letrozole/abemaciclib/LY3023414 in endometrial cancer

• Prif Awduron: Panagiotis A. Konstantinopoulos (Awdur), Niya Xiong (Awdur), Carolyn Krasner (Awdur), Joyce F. Liu (Awdur), Hannah Sawyer (Awdur), Madeline Polak (Awdur), Hope Needham (Awdur), Megan Geddes (Awdur), Lani Koppermann (Awdur), Meghan Shea (Awdur), Cesar Castro (Awdur), Su-Chun Cheng (Awdur), Ursula A. Matulonis (Awdur), Elizabeth K. Lee (Awdur)
• Fformat: Llyfr
• Cyhoeddwyd: Elsevier, 2024-04-01T00:00:00Z.
• Pynciau: article
• Mynediad Ar-lein: Connect to this object online.

Several lines of preclinical evidence indicate that combining PI3K and CDK4/6 inhibitors may further enhance the efficacy of hormonal therapy by overcoming de novo and acquired resistance to PI3K and CDK4/6 blockade. We evaluated the combination of abemaciclib, letrozole and LY3023414 (an orally ava...